Scholar Rock price to sales ratio SRRK

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 11.6×; Aug 2023
7-year median: 22.2×
7-year range: 3.7× to 144×
Peer median: 7.5×

Scholar Rock's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2023, at 11.6×.

On the days it had one over the last 7 years, its median was 22.2×, from 3.7× in May 2022 to 144× in Mar 2021.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	11.6×	10.0×	17.6×
2022	12.6×	3.7×	41.3×
2021	47.9×	47.9×	144×
2020	83.5×	14.8×	88.7×

Against its peers

Companies in Biotechnology nearest Scholar Rock's size, closest first, today.

Company	Price to sales ratio
SRRKScholar Rock	n/m
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
ADMAAdma Biologics	4.7×
TECHBIO-TECHNE	9.4×
VCELVericel	7.1×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
INCYIncyte	4.0×
UTHRUnited Therapeutics	8.0×
Peer median	7.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Scholar Rock

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.